UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

High prevalence of MAP2K1 mutations in variant and IGHV4-34–expressing hairy-cell leukemias

Nature genetics, 2014-01, Vol.46 (1), p.8-10

2014

Volltextzugriff (PDF)

Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia

Journal of clinical oncology, 2012-05, Vol.30 (15), p.1822-1828

2012

Volltextzugriff (PDF)

Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P

Clinical cancer research, 2009-08, Vol.15 (16), p.5274-5279

2009

Volltextzugriff (PDF)

Immunotoxins for leukemia

Blood, 2014-04, Vol.123 (16), p.2470-2477

2014

Volltextzugriff (PDF)

Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes

Proceedings of the National Academy of Sciences - PNAS, 2012-07, Vol.109 (29), p.11782-11787

2012

Volltextzugriff (PDF)

Immunotoxin treatment of cancer

Annual review of medicine, 2007-01, Vol.58 (1), p.221-237

2007

Volltextzugriff (PDF)

Characterization of CD22 expression in acute lymphoblastic leukemia

Pediatric blood & cancer, 2015-06, Vol.62 (6), p.964-969

2015

Volltextzugriff (PDF)

Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers

Clinical cancer research, 2007-09, Vol.13 (17), p.5144-5149

2007

Volltextzugriff (PDF)

Immunotoxins: From Design to Clinical Application

Biomolecules (Basel, Switzerland), 2021-11, Vol.11 (11), p.1696

2021

Volltextzugriff (PDF)

Recombinant Immunotoxins Containing Truncated Bacterial Toxins for the Treatment of Hematologic Malignancies

BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 2009, Vol.23 (1), p.1-13

Kreitman, Robert J.

2009

Volltextzugriff (PDF)

Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia

Blood, 2017-10, Vol.130 (14), p.1620-1627

2017

Volltextzugriff (PDF)

Development of Recombinant Immunotoxins for Hairy Cell Leukemia

Biomolecules (Basel, Switzerland), 2020-08, Vol.10 (8), p.1140

2020

Volltextzugriff (PDF)

Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes

Proceedings of the National Academy of Sciences - PNAS, 2014-06, Vol.111 (23), p.8571-8576

2014

Volltextzugriff (PDF)

Phase II Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With Hairy Cell Leukemia

Journal of clinical oncology, 2009-06, Vol.27 (18), p.2983-2990

2009

Volltextzugriff (PDF)

Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial

Journal of hematology and oncology, 2021-02, Vol.14 (1), p.35-11, Article 35

2021

Volltextzugriff (PDF)

Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience

Haematologica (Roma), 2023-06, Vol.108 (6), p.1676-1679

2023

Volltextzugriff (PDF)

Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes

Proceedings of the National Academy of Sciences - PNAS, 2011-04, Vol.108 (14), p.5742-5747

2011

Volltextzugriff (PDF)

Hairy cell leukemia: present and future directions

Leukemia & lymphoma, 2019-10, Vol.60 (12), p.2869-2879

Kreitman, Robert J.

2019

Volltextzugriff (PDF)

Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial

Clinical cancer research, 2010-03, Vol.16 (6), p.1894-1903

2010

Volltextzugriff (PDF)

Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox

Clinical cancer research, 2011-10, Vol.17 (20), p.6398-6405

2011

Volltextzugriff (PDF)

Effect of antigen shedding on targeted delivery of immunotoxins in solid tumors from a mathematical model

PloS one, 2014-10, Vol.9 (10), p.e110716

2014

Volltextzugriff (PDF)

Expression of the muscle-associated gene MYF6 in hairy cell leukemia

PloS one, 2020-02, Vol.15 (2), p.e0227586-e0227586

2020

Volltextzugriff (PDF)

Phase I Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With B-Cell Malignancies

Journal of clinical oncology, 2005-09, Vol.23 (27), p.6719-6729

2005

Volltextzugriff (PDF)

Efficacy of the Anti-CD22 Recombinant Immunotoxin BL22 in Chemotherapy-Resistant Hairy-Cell Leukemia

The New England journal of medicine, 2001-07, Vol.345 (4), p.241-247

2001

Volltextzugriff (PDF)

CAT-8015: A Second-Generation Pseudomonas Exotoxin A–Based Immunotherapy Targeting CD22-Expressing Hematologic Malignancies

Clinical cancer research, 2009-02, Vol.15 (3), p.832-839

2009

Volltextzugriff (PDF)

1 – 25 von 330

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(316)
Mit Volltextzugriff
(299)

Publikationsform

Sprache

Englisch
(330)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

High prevalence of MAP2K1 mutations in variant and IGHV4-34–expressing hairy-cell leukemias

Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia

Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P

Immunotoxins for leukemia

Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes

Immunotoxin treatment of cancer

Characterization of CD22 expression in acute lymphoblastic leukemia

Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers

Immunotoxins: From Design to Clinical Application

Recombinant Immunotoxins Containing Truncated Bacterial Toxins for the Treatment of Hematologic Malignancies

Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia

Development of Recombinant Immunotoxins for Hairy Cell Leukemia

Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes

Phase II Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With Hairy Cell Leukemia

Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial

Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience

Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes

Hairy cell leukemia: present and future directions

Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial

Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox

Effect of antigen shedding on targeted delivery of immunotoxins in solid tumors from a mathematical model

Expression of the muscle-associated gene MYF6 in hairy cell leukemia

Phase I Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With B-Cell Malignancies

Efficacy of the Anti-CD22 Recombinant Immunotoxin BL22 in Chemotherapy-Resistant Hairy-Cell Leukemia

CAT-8015: A Second-Generation Pseudomonas Exotoxin A–Based Immunotherapy Targeting CD22-Expressing Hematologic Malignancies

Suchergebnisse filtern